XML 42 R25.htm IDEA: XBRL DOCUMENT
v3.25.4

Segment Information | 12 Months Ended
--- | ---
Dec. 31, 2025
Segment Reporting [Abstract] |
Segment Information | Segment Information During the year ended December 31, 2024, the Company renamed its Technologies segment as "Nuclear & Safety." The Company manages its operations through two operating and reportable segments: Medical and Nuclear & Safety. These segments align the Company’s products and service offerings to customers and are consistent with how the Company’s Chief Executive Officer, its Chief Operating Decision Maker (“CODM”), reviews and evaluates the Company’s operations. The CODM allocates resources and evaluates the financial performance of each operating segment using operating income (loss). The Company’s segments are strategic businesses that are managed separately because each one develops, manufactures, and markets distinct products and services. The company adopted ASU 2023-07 “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” as of the year ended December 31, 2024, and applied the requirements of the standard to prior period information retrospectively as required. Description of Segments The Medical segment provides solutions focused on ensuring safety of equipment and personnel in the medical field. The primarily product category relates to Cancer Care applications, including radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world, radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy, and radionuclide therapy products for nuclear medicine applications such as product handling and medical imaging furniture. Other Medical segment products include dosimetry solutions for monitoring the total amount of radiation medical staff members are exposed to over time, The Nuclear & Safety segment provides radiation detection equipment for power plants, labs and research facilities and industrial and defense applications. Nuclear products are concentrated in power plant product offerings that are used for the full nuclear power plant lifecycle including core detectors and essential measurement devices for new build, maintenance, decontamination and decommission equipment for monitoring and control during fuel dismantling, and remote environmental monitoring. Labs and research and other (primarily industrial and defense) are focused on the area of personal radiation detection for various safety and security requirements. The CODM evaluates operating results and allocates capital resources between segments based on segment operating income (loss). Interest income and expense, loss (benefit) from income taxes, foreign currency loss (gain), net, other expense (income), net, and, if applicable, other items such as loss on debt extinguishment, are not allocated to segments. The following tables summarize information about revenue, significant segment expenses, other segment items, and segment income (loss) from operations for each reportable segment (in millions). Reconciliation of consolidated segment income (loss) from operations to consolidated income (loss) before income taxes is shown in the Total column of each table.
| Fiscal Year Ended December 31, 2025
| Medical |  | Nuclear & Safety |  | Total
Revenues | $ | 310.8 |  |  | $ | 614.6 |  |  | $ | 925.4 |
Less: |  |  |  |  |
Adjusted cost of revenues 1 | 109.0 |  |  | 324.0 |  |  | 433.0 |
Other segment items 2 | 154.9 |  |  | 189.5 |  |  | 344.4 |
Segment income from operations | $ | 46.9 |  |  | $ | 101.1 |  |  | $ | 148.0 |
Other loss 3 |  |  |  |  | (96.5) |
Income from operations |  |  |  |  | 51.5 |
Less other expense (income): |  |  |  |  |
Interest expense |  |  |  |  | 42.2 |
Interest income |  |  |  |  | (12.1) |
Loss on debt extinguishment |  |  |  |  | 5.8 |
Foreign currency (gain)/loss, net |  |  |  |  | (17.4) |
Other income, net |  |  |  |  | 0.3 |
Consolidated income before income taxes |  |  |  |  | $ | 32.7 |
| Fiscal Year Ended December 31, 2024
| Medical |  | Nuclear & Safety |  | Total
Revenues | $ | 299.7 |  |  | $ | 561.1 |  |  | $ | 860.8 |
Less: |  |  |  |  |
Adjusted cost of revenues 1 | 108.7 |  |  | 300.4 |  |  | 409.1 |
Other segment items 2 | 168.7 |  |  | 181.8 |  |  | 350.5 |
Segment income from operations | $ | 22.3 |  |  | $ | 78.9 |  |  | $ | 101.2 |
Other loss 3 |  |  |  |  | (76.4) |
Income from operations |  |  |  |  | 24.8 |
Less other expense (income): |  |  |  |  |
Interest expense |  |  |  |  | 57.9 |
Interest income |  |  |  |  | (6.6) |
Foreign currency (gain)/loss, net |  |  |  |  | 2.2 |
Increase in fair value of warrant liabilities |  |  |  |  | 5.3 |
Other income, net |  |  |  |  | (0.1) |
Consolidated loss before income taxes |  |  |  |  | $ | (33.9) |
| Fiscal Year Ended December 31, 2023
| Medical |  | Nuclear & Safety |  | Total
Revenues | $ | 284.5 |  |  | $ | 516.4 |  |  | $ | 800.9 |
Less: |  |  |  |  |
Adjusted cost of revenues 1 | 107.3 |  |  | 289.6 |  |  | 396.9 |
Other segment items 2 | 164.2 |  |  | 180.8 |  |  | 345.0 |
Segment income from operations | $ | 13.0 |  |  | $ | 46.0 |  |  | $ | 59.0 |
Other loss 3 |  |  |  |  | (80.9) |
Loss from operations |  |  |  |  | (21.9) |
Less other expense (income): |  |  |  |  |
Interest expense |  |  |  |  | 61.9 |
Interest income |  |  |  |  | (4.8) |
Loss on debt extinguishment |  |  |  |  | 2.6 |
Foreign currency (gain)/loss, net |  |  |  |  | (0.3) |
Increase in fair value of warrant liabilities |  |  |  |  | 24.8 |
Other income, net |  |  |  |  | (0.8) |
Consolidated loss before income taxes |  |  |  |  | $ | (105.3) |
1 | Adjusted cost of revenues is a significant expense category, and amounts align with the segment-level information that is regularly provided to the CODM. Adjusted cost of revenues is defined by management as cost of revenues adjusted for purchase accounting impacts and excluding depreciation, amortization, and other segment expenses identified as non-operating by management.
2 | Other segment items included in segment income (loss) from operations for each segment include research and development expenses; selling and marketing expenses; general and administrative expenses; and any amounts excluded from cost of revenues to determine adjusted costs of revenues (e.g., depreciation, amortization, and other segment expenses identified as non-operating by management).
3 | Other loss consists of research and development expenses; selling and marketing expenses; and general and administrative expenses not allocated to the segments.
The Company’s assets by reportable segment were not included, as this information is not reviewed by, nor otherwise provided to, the CODM to make operating decisions or allocate resources. The following table summarizes capital expenditures and depreciation and amortization for each reportable segment (in millions).
| Fiscal Year Ended December 31, 2025 |  | Fiscal Year Ended December 31, 2024 |  | Fiscal Year Ended December 31, 2023
Capital expenditures |  |  |  |  |
Medical | $ | 20.2 |  |  | $ | 27.8 |  |  | $ | 21.8 |
Nuclear & Safety | 18.7 |  |  | 17.7 |  |  | 18.0 |
Total operating and reportable segments | 38.9 |  |  | 45.5 |  |  | 39.8 |
Corporate and other | 0.7 |  |  | 3.3 |  |  | 1.0 |
Total capital expenditures | $ | 39.6 |  |  | $ | 48.8 |  |  | $ | 40.8 |
Depreciation and amortization |  |  |  |  |
Medical | $ | 65.5 |  |  | $ | 73.0 |  |  | $ | 75.2 |
Nuclear & Safety | 71.6 |  |  | 76.7 |  |  | 86.9 |
Total operating and reportable segments | 137.1 |  |  | 149.7 |  |  | 162.1 |
Corporate and other | 1.0 |  |  | 0.7 |  |  | 0.7 |
Total depreciation and amortization | $ | 138.1 |  |  | $ | 150.4 |  |  | $ | 162.8 |
The following details revenues by geographic region. Revenues generated from external customers are attributed to geographic regions through sales from site locations (i.e. point of origin) (in millions).
| Revenues
| Fiscal Year Ended December 31, 2025 |  | Fiscal Year Ended December 31, 2024 |  | Fiscal Year Ended December 31, 2023
North America |  |  |  |  |
Medical | $ | 279.3 |  |  | $ | 271.9 |  |  | $ | 258.1 |
Nuclear & Safety | 302.9 |  |  | 270.3 |  |  | 254.2 |
Total North America | 582.2 |  |  | 542.2 |  |  | 512.3 |
Europe |  |  |  |  |
Medical | 31.5 |  |  | 27.8 |  |  | 26.4 |
Nuclear & Safety | 296.1 |  |  | 277.8 |  |  | 245.7 |
Total Europe | 327.6 |  |  | 305.6 |  |  | 272.1 |
Asia Pacific |  |  |  |  |
Medical | — |  |  | — |  |  | — |
Nuclear & Safety | 15.6 |  |  | 13.0 |  |  | 16.5 |
Total Asia Pacific | 15.6 |  |  | 13.0 |  |  | 16.5 |
Total Revenues | $ | 925.4 |  |  | $ | 860.8 |  |  | $ | 800.9 |
Revenues generated in the United States were $525.9 million, $497.9 million, and $476.0 million for the fiscal years ended December 31, 2025, December 31, 2024 and December 31, 2023, respectively. Revenues in France were $193.7 million, $181.5 million, and $155.4 million for the fiscal years ended December 31, 2025, December 31, 2024 and December 31, 2023, respectively. No other country generated more than 10% of revenue individually. The following details revenues by timing of recognition (in millions):
| Revenues
| Fiscal Year Ended December 31, 2025 |  | Fiscal Year Ended December 31, 2024 |  | Fiscal Year Ended December 31, 2023
Point in time | $ | 620.2 |  |  | $ | 567.0 |  |  | $ | 496.0 |
Over time | 305.2 |  |  | 293.8 |  |  | 304.9 |
Total revenues | $ | 925.4 |  |  | $ | 860.8 |  |  | $ | 800.9 |
The following details revenues by product for each segment (in millions). The Company updated the categorization of its products to better align with the markets driving demand. The revenues by product information has been recast for all prior periods presented.
| Revenues
| Fiscal Year Ended December 31, 2025 |  | Fiscal Year Ended December 31, 2024 |  | Fiscal Year Ended December 31, 2023
Medical segment: |  |  |  |  |
Cancer care | $ | 237.0 |  |  | $ | 228.1 |  |  | $ | 215.9 |
Other | 73.8 |  |  | 71.6 |  |  | 68.6 |
Nuclear & Safety segment: |  |  |  |  |
Nuclear | 374.6 |  |  | 316.6 |  |  | 291.8 |
Labs and research | 122.2 |  |  | 131.7 |  |  | 122.9 |
Other | 117.8 |  |  | 112.8 |  |  | 101.7 |
Total Revenues | $ | 925.4 |  |  | $ | 860.8 |  |  | $ | 800.9 |
The following details property, plant, and equipment, net, by geography (in millions):
| Property, Plant, and Equipment, Net
| December 31, 2025 |  | December 31, 2024
North America | $ | 93.4 |  |  | $ | 91.5 |
Europe | 61.4 |  |  | 54.7 |
Asia Pacific | 0.1 |  |  | 0.1 |
Total | $ | 154.9 |  |  | $ | 146.3 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration